Top 10 Insider Purchases Last Month

8. Arcus Biosciences, Inc. (NYSE:RCUS)

Total value of insider purchases in February: $15,402,661.00

Market capitalization: $1.01 billion

Arcus Biosciences is a clinical-stage biopharmaceutical company engaged in the development of best-in-class molecules and combination therapies for cancer patients. Among the company’s leading candidates are Domvanalimab, an anti-TIGIT antibody currently in Phase 2 and Phase 3 clinical trials, and AB308, an investigational anti-TIGIT monoclonal antibody in a Phase 1b clinical trial studying patients with advanced solid and hematologic malignancies. TIGIT is a checkpoint protein found on immune cells in the tumor microenvironment that inhibits the immune system’s natural ability to detect and kill cancer cells.

In February, three insiders acquired a total of $15.40 million worth of Arcus shares at an average price of $10.41 per share. Currently, the stock is trading at $9.46 per share, having lost 36.47% year-to-date, and 49.25% over the past 12 months.

Ten analysts have rated Arcus stock as “Buy” and projected a price of $30.25, according to MarketBeat. The average price target represents a forecasted upside of 219.16% from the latest price.